-
公开(公告)号:US09149465B2
公开(公告)日:2015-10-06
申请号:US12782650
申请日:2010-05-18
申请人: Mark L. Behnke , Alfredo C. Castro , Lawrence K. Chan , Catherine A. Evans , Louis Grenier , Michael J. Grogan , Yves Leblanc , Tao Liu , Stephane Peluso , Daniel A. Snyder , Thomas T. Tibbitts
发明人: Mark L. Behnke , Alfredo C. Castro , Lawrence K. Chan , Catherine A. Evans , Louis Grenier , Michael J. Grogan , Yves Leblanc , Tao Liu , Stephane Peluso , Daniel A. Snyder , Thomas T. Tibbitts
IPC分类号: C07D261/04 , A61K31/5377 , A61K31/42 , A61K31/4245 , A61K31/4439 , A61K31/4709 , A61K31/501 , A61K31/506 , C07D413/04 , C07D413/12 , C07D413/14 , C07D471/04
CPC分类号: A61K31/42 , A61K31/4245 , A61K31/4439 , A61K31/4709 , A61K31/501 , A61K31/506 , A61K31/5377 , C07D261/04 , C07D413/04 , C07D413/12 , C07D413/14 , C07D471/04
摘要: The present invention provides isoxazoline FAAH inhibitors of the formula (I): or pharmaceutically acceptable forms thereof, wherein each of G, Ra, Rb, Rc, and Rd are as defined herein. The present invention also provides pharmaceutical compositions comprising a compound of formula (I), or a pharmaceutically acceptable form thereof, and a pharmaceutically acceptable excipient.The present invention also provides methods for treating an FAAH-mediated condition comprising administering a therapeutically effective amount of a compound of formula (I), or pharmaceutically acceptable form thereof, to a subject in need thereof.
摘要翻译: 本发明提供式(I)的异恶唑啉FAAH抑制剂或其药学上可接受的形式,其中G,Ra,Rb,Rc和Rd各自如本文所定义。 本发明还提供包含式(I)化合物或其药学上可接受的形式的药物组合物和药学上可接受的赋形剂。 本发明还提供了治疗FAAH介导的病症的方法,包括向有需要的受试者施用治疗有效量的式(I)化合物或其药学上可接受的形式。
-
公开(公告)号:US09056877B2
公开(公告)日:2015-06-16
申请号:US13552473
申请日:2012-07-18
申请人: Alfredo C. Castro , Catherine A. Evans , Andre Lescarbeau , Tao Liu , Daniel A. Snyder , Martin R. Tremblay , Pingda Ren , Yi Liu , Liansheng Li , Katrina Chan
发明人: Alfredo C. Castro , Catherine A. Evans , Andre Lescarbeau , Tao Liu , Daniel A. Snyder , Martin R. Tremblay , Pingda Ren , Yi Liu , Liansheng Li , Katrina Chan
IPC分类号: C07D277/20 , C07D513/04
CPC分类号: C07D513/04 , A61K31/519 , C07D519/00
摘要: Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.
-
公开(公告)号:US08765735B2
公开(公告)日:2014-07-01
申请号:US12782658
申请日:2010-05-18
申请人: Mark L. Behnke , Alfredo C. Castro , Lawrence K. Chan , Catherine A. Evans , Louis Grenier , Michael J. Grogan , Yves Leblanc , Tao Liu , Stephane Peluso , Daniel A. Snyder , Thomas T. Tibbitts
发明人: Mark L. Behnke , Alfredo C. Castro , Lawrence K. Chan , Catherine A. Evans , Louis Grenier , Michael J. Grogan , Yves Leblanc , Tao Liu , Stephane Peluso , Daniel A. Snyder , Thomas T. Tibbitts
IPC分类号: A01N43/00 , A61K31/55 , A01N43/42 , A61K31/44 , A01N43/80 , A61K31/42 , C07D261/02 , C07D401/00
CPC分类号: C07D498/10 , A61K31/42 , A61K31/438 , A61K31/55 , C07D261/20 , C07D498/04
摘要: The present invention provides isoxazoline FAAH inhibitors of the formula (I): or pharmaceutically acceptable forms thereof, wherein each of G, Ra, Rb, Rc, and Rd are as defined herein. The present invention also provides pharmaceutical compositions comprising a compound of formula (I), or a pharmaceutically acceptable form thereof, and a pharmaceutically acceptable excipient.The present invention also provides methods for treating an FAAH-mediated condition comprising administering a therapeutically effective amount of a compound of formula (I), or pharmaceutically acceptable form thereof, to a subject in need thereof.
摘要翻译: 本发明提供式(I)的异恶唑啉FAAH抑制剂或其药学上可接受的形式,其中G,Ra,Rb,Rc和Rd各自如本文所定义。 本发明还提供包含式(I)化合物或其药学上可接受的形式的药物组合物和药学上可接受的赋形剂。 本发明还提供了治疗FAAH介导的病症的方法,包括向有需要的受试者施用治疗有效量的式(I)化合物或其药学上可接受的形式。
-
公开(公告)号:US20130029984A1
公开(公告)日:2013-01-31
申请号:US13552473
申请日:2012-07-18
申请人: Alfredo C. Castro , Catherine A. Evans , Andre Lescarbeau , Tao Liu , Daniel A. Snyder , Martin R. Tremblay , Pingda Ren , Yi Liu , Liansheng Li , Katrina Chan
发明人: Alfredo C. Castro , Catherine A. Evans , Andre Lescarbeau , Tao Liu , Daniel A. Snyder , Martin R. Tremblay , Pingda Ren , Yi Liu , Liansheng Li , Katrina Chan
IPC分类号: A61K31/519 , A61K31/5377 , A61K31/4725 , A61P37/06 , C07D495/04 , A61P35/00 , A61P29/00 , C07D513/04 , A61K31/506
CPC分类号: C07D513/04 , A61K31/519 , C07D519/00
摘要: Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.
-
公开(公告)号:US20110230440A1
公开(公告)日:2011-09-22
申请号:US13049785
申请日:2011-03-16
申请人: Julian Adams , Mark L. Behnke , Alfredo C. Castro , Catherine A. Evans , Louis Grenier , Michael J. Grogan , Tao Liu , Daniel A. Snyder , Thomas T. Tibbitts
发明人: Julian Adams , Mark L. Behnke , Alfredo C. Castro , Catherine A. Evans , Louis Grenier , Michael J. Grogan , Tao Liu , Daniel A. Snyder , Thomas T. Tibbitts
IPC分类号: A61K31/69 , C07F5/02 , A61P29/00 , A61P25/00 , A61P37/00 , A61P25/22 , A61P25/24 , A61P27/06 , A61P9/00
摘要: The present invention provide compounds, and pharmaceutical compositions thereof, encompassed by the formulae (I), (II) or (III). The present invention also provides methods for treating an FAAH mediated disease, disorder or condition by administering a therapeutically effective amount of a provided compound of the formulae (I), (II) or (III), or a pharmaceutical composition thereof, to a patient in need thereof. Additionally, the present invention provides methods for inhibiting FAAH in a patient by administering a therapeutically effective amount of a compound of the formulae (I), (II) or (III), or a pharmaceutical composition thereof, to a patient in need thereof.
-
公开(公告)号:US20110028478A1
公开(公告)日:2011-02-03
申请号:US12782650
申请日:2010-05-18
申请人: Mark L. Behnke , Alfredo C. Castro , Lawrence K. Chan , Catherine A. Evans , Louis Grenier , Michael J. Grogan , Yves Leblanc , Tao Liu , Stephane Peluso , Daniel A. Snyder , Thomas T. Tibbitts
发明人: Mark L. Behnke , Alfredo C. Castro , Lawrence K. Chan , Catherine A. Evans , Louis Grenier , Michael J. Grogan , Yves Leblanc , Tao Liu , Stephane Peluso , Daniel A. Snyder , Thomas T. Tibbitts
IPC分类号: A61K31/5377 , C07D261/04 , A61K31/42 , A61P29/00 , A61P27/06 , A61P9/10 , A61P37/00 , A61P17/00 , A61P25/28 , A61P1/08 , A61P25/30 , A61P9/12 , A61P3/04 , C07D413/12 , A61K31/4439 , A61K31/506 , A61K31/501 , C07D413/10 , A61K31/4245 , A61K31/4709
CPC分类号: A61K31/42 , A61K31/4245 , A61K31/4439 , A61K31/4709 , A61K31/501 , A61K31/506 , A61K31/5377 , C07D261/04 , C07D413/04 , C07D413/12 , C07D413/14 , C07D471/04
摘要: The present invention provides isoxazoline FAAH inhibitors of the formula (I): or pharmaceutically acceptable forms thereof, wherein each of G, Ra, Rb, Rc, and Rd are as defined herein. The present invention also provides pharmaceutical compositions comprising a compound of formula (I), or a pharmaceutically acceptable form thereof, and a pharmaceutically acceptable excipient.The present invention also provides methods for treating an FAAH-mediated condition comprising administering a therapeutically effective amount of a compound of formula (I), or pharmaceutically acceptable form thereof, to a subject in need thereof.
-
公开(公告)号:US08957049B2
公开(公告)日:2015-02-17
申请号:US12901421
申请日:2010-10-08
申请人: Mark L. Behnke , Alfredo C. Castro , Catherine A. Evans , Louis Grenier , Michael J. Grogan , Tao Liu , Daniel A. Snyder , Thomas T. Tibbitts
发明人: Mark L. Behnke , Alfredo C. Castro , Catherine A. Evans , Louis Grenier , Michael J. Grogan , Tao Liu , Daniel A. Snyder , Thomas T. Tibbitts
摘要: The present invention provides compounds, and pharmaceutically acceptable compositions thereof, encompassed by any of formulae (I), (II), (III), (IV), (V), or (VI), or subgenera thereof. The present invention also provides methods for treating an FAAH mediated disease, disorder or condition by administering a therapeutically effective amount of a compound or composition comprising a compound of any of formulae (I), (II), (III), (IV), (V), or (VI), or subgenera thereof, to a patient in need thereof. Additionally, the present invention provides methods for inhibiting FAAH by administering a therapeutically effective amount of a compound or composition comprising a compound of any of formulae (I), (II), (III), (IV), (V), or (VI), or subgenera thereof, to a patient in need thereof.
摘要翻译: 本发明提供了由式(I),(II),(III),(IV),(V)或(VI)或其子类中的任何一种包含的化合物及其药学上可接受的组合物。 本发明还提供了通过施用治疗有效量的化合物或组合物来治疗FAAH介导的疾病,病症或病症的方法,所述化合物或组合物包含式(I),(II),(III),(IV), (Ⅴ)或(Ⅵ)或其子代的药物给予有需要的患者。 另外,本发明提供了通过施用治疗有效量的包含式(I),(II),(III),(IV),(V)或((IV))的化合物的化合物或组合物来抑制FAAH的方法, VI)或其子集合。
-
8.
公开(公告)号:US20120059000A1
公开(公告)日:2012-03-08
申请号:US13112611
申请日:2011-05-20
申请人: Pingda Ren , Yi Liu , Liansheng Li , Katrina Chan , Alfredo C. Castro , Catherine A. Evans
发明人: Pingda Ren , Yi Liu , Liansheng Li , Katrina Chan , Alfredo C. Castro , Catherine A. Evans
IPC分类号: A61K31/5377 , A61K31/496 , A61K31/52 , A61K31/519 , A61P29/00 , C07D487/04 , C07D401/14 , A61P37/02 , A61P35/00 , A61K31/53 , A61K31/506
CPC分类号: C07D473/34 , A61K31/47 , A61K31/52 , C07D401/14 , C07D473/16 , C07D473/32 , C07D487/04 , Y02A50/414 , Y02A50/463
摘要: Chemical compounds that modulate kinase activity, including PI3 kinase activity, and chemical compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including P13 kinase activity, are described herein.
摘要翻译: 本文描述了调节激酶活性的化合物,包括PI3激酶活性和化学化合物,药物组合物以及治疗与激酶活性(包括P13激酶活性)相关的疾病和病症的方法。
-
公开(公告)号:US08901133B2
公开(公告)日:2014-12-02
申请号:US13293828
申请日:2011-11-10
申请人: Pingda Ren , Yi Liu , Liansheng Li , Katrina Chan , Troy Edward Wilson , Alfredo C. Castro , Catherine A. Evans , Daniel A. Snyder
发明人: Pingda Ren , Yi Liu , Liansheng Li , Katrina Chan , Troy Edward Wilson , Alfredo C. Castro , Catherine A. Evans , Daniel A. Snyder
IPC分类号: A61K31/519 , C07D471/04 , C07D487/04 , C07D519/00 , C07D401/12 , C07D473/34 , C07D513/04
CPC分类号: C07D473/34 , C07D401/12 , C07D413/14 , C07D471/04 , C07D487/04 , C07D513/04 , C07D519/00
摘要: Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.
摘要翻译: 本文描述了调节激酶活性(包括PI3激酶活性)的化合物和药物组合物,以及化合物,药物组合物和治疗与激酶活性(包括PI3激酶活性)相关的疾病和病症的方法。
-
公开(公告)号:US20130053362A1
公开(公告)日:2013-02-28
申请号:US13552516
申请日:2012-07-18
申请人: Alfredo C. CASTRO , Catherine A. EVANS , Somarajannair JANARDANANNAIR , Andre LESCARBEAU , Tao LIU , Daniel A. SNYDER , Martin R. TREMBLAY , Pingda REN , Yi LIU , Liansheng LI , Katrina CHAN
发明人: Alfredo C. CASTRO , Catherine A. EVANS , Somarajannair JANARDANANNAIR , Andre LESCARBEAU , Tao LIU , Daniel A. SNYDER , Martin R. TREMBLAY , Pingda REN , Yi LIU , Liansheng LI , Katrina CHAN
IPC分类号: A61K31/506 , C07D401/12 , C07D471/04 , C07D403/12 , A61K31/517 , A61P37/00 , C07D417/14 , C07D413/14 , C07D405/14 , A61K31/5377 , A61P35/00 , A61P29/00 , C07D401/14 , C07D403/14
CPC分类号: C07D401/14 , A61K31/506 , A61K31/517 , A61K31/5377 , A61K45/06 , C07D401/12 , C07D403/12 , C07D403/14 , C07D405/14 , C07D411/14 , C07D413/14 , C07D417/14 , C07D471/04 , C07D487/04 , C07D495/04 , C07D513/04 , C12N9/1205 , C12Y207/01137 , Y02A50/414
摘要: Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including P13 kinase activity, are described herein.
摘要翻译: 本文描述了调节激酶活性(包括PI3激酶活性)的化合物和药物组合物,以及化合物,药物组合物和治疗与激酶活性(包括P13激酶活性)相关的疾病和病症的方法。
-
-
-
-
-
-
-
-
-